stockrow
Friday 6 November 2026
Export OPTH’s income statement to Excel — free account
Optimi Health Corp.
OPTH Healthcare Drug Manufacturers Specialty & Generic
Optimi Health Corp.’s revenue for fiscal 2025 (year ended September 2025) was $304,800.00, up 6.39% from fiscal 2024.
2.29
0.08
+3.62%
Follow OPTH
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to September
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Mar ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 0 | 0 | — | +3.1% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | 69.49 | 69.49 | (15.98) | — | (85.5) pt | ||||||
| EBT | — | — | — | — | — | — | — | (4) | (4) | (3) | — | (22.7%) | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (1,548.27) | (1,548.27) | (870.64) | — | +677.6 pt | ||||||
| Net income | — | — | — | — | — | — | — | 0 | (4) | (3) | (8) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.10 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (0.05) | (0.83) | — | +1,576.0% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (0.04) | (0.59) | (1.48) | +1,573.2% | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | (0.02) | (0.04) | +1,423.1% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.04) | (0.61) | (1.52) | +1,567.6% | ||||||
| Book value | — | — | — | — | — | — | — | 0.00 | 0.08 | 1.47 | 0.80 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 90 | 3 | — | (96.4%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 142.93 | 2.86 | 47.6 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (2.03) | 0.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (3) | (2) | (5) | (40.3%) | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | 0 | (43.6%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (3) | (2) | (5) | (40.4%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (1) | (1) | (5) | (7) | +80.7% | |||||
| Net debt | — | — | — | — | — | — | — | 0 | 0 | 2 | 3 | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 7 | 7 | 5 | 3 | (18.3%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | (41.48) | (41.48) | (24.61) | — | +16.9 pt | |||||
| ROIC | — | — | — | — | — | — | — | (32.42) | (36.21) | (35.59) | 0.00 | (3.2) pt | ||||||
| ROE | — | — | — | — | — | — | — | 25.56 | 86.01 | (45.23) | — | (70.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 10 | 10 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.03 | 0.03 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Sep 2025 · latest quarter Mar 2026 · fundamentals updated 2 Nov 2026
Optimi Health Corp. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $24.0M | — (loss-making) | — | — | n/m | +82.01% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CPHI China Pharma Holdings, Inc. | $22.8M | — (loss-making) | — (loss-making) | −7.56% (below 0%: shrinking) | n/m | −113.57% (below 0%: shrinking) | 8.82% | (150.99%) | Compare |
| TXMD TherapeuticsMD, Inc. | $19.8M | — (loss-making) | 18.9× | −8.72% (below 0%: shrinking) | −80.00% (below 0%: shrinking) | +104.46% (above 0%: growing) | 100.00% | (93.90%) | Compare |
| AYTU Aytu BioPharma, Inc. | $19.7M | — (loss-making) | — (loss-making) | +6.42% (above 0%: growing) | n/m | +57.72% (above 0%: growing) | 64.63% | (4.82%) | Compare |
| OPTH Optimi Health Corp. | $13.7M | — | — | — | n/m | — | 89.93% | (1,364.28%) | |
| BFRI Biofrontera Inc. | $12.0M | — (loss-making) | — (loss-making) | +32.92% (above 0%: growing) | n/m | +45.57% (above 0%: growing) | 79.92% | (4.37%) | Compare |
| INM InMed Pharmaceuticals Inc. | $7.3M | — (loss-making) | — | −26.22% (below 0%: shrinking) | n/m | +40.84% (above 0%: growing) | 22.46% | 0.00% | Compare |
| UPC Universe Pharmaceuticals INC | $7.0M | — (loss-making) | 4.1× | −23.98% (below 0%: shrinking) | −110.15% (below 0%: shrinking) | −84.99% (below 0%: shrinking) | 32.57% | 0.00% | Compare |
| SNOA Sonoma Pharmaceuticals, Inc. | $5.1M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | Compare |
| Median of peers | $15.8M | — | — | −7.56% | — | +51.65% | 36.40% | (2.49%) |